NYBC Ventures general partner Jay Mohr and managing director Meg Wood (NYBC Ventures)

New blood and cell ther­a­py-fo­cused ven­ture fund emerges with $50M and a Jen­nifer Doud­na spin­out in tow

A $50 mil­lion ven­ture fund ded­i­cat­ed to blood-re­lat­ed fields and cell ther­a­pies emerged Thurs­day af­ter spend­ing about a year build­ing out its ini­tial in­vest­ments in a hand­ful of star­tups, in­clud­ing a Jen­nifer Doud­na spin­out work­ing on new can­cer and au­toim­mune ther­a­peu­tics.

The 60-year-old New York Blood Cen­ter, a non­prof­it that de­liv­ers blood prod­ucts, trans­fu­sion med­i­cine ser­vices and blood re­search across 17 states, has cre­at­ed the NY­BC Ven­tures fund to back star­tups work­ing on be­nign hema­tol­ogy, in­fec­tious dis­eases, cell ther­a­pies, de­vices, trans­fu­sion med­i­cine and oth­er ar­eas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA